The Power To Lower Blood Pressure

About InterCure, Manufacturer of RESPeRATE

• InterCure Ltd. (Tel-Aviv Stock Exchange: INCR), a medical device company, is successfully selling the world’s first, FDA-cleared, non-drug, non-invasive hypertension treatment device RESPeRATE.^®
• InterCure’s broadly patented Device-Guided Breathing platform, which RESPeRATE uses, enables a systematic reduction in sympathetic outflow of the autonomous nervous system, one of the key underlining causes for cardiovascular disease, insomnia and multiple other conditions.
• Headquartered from New York, NY and Lod Israel, InterCure is a publicly traded Israeli company founded in 1994 by Dr. Benjamin Gavish and Erez Gavish. InterCure also operates a marketing office in London, outsourced call centers/warehouses in NJ, Southampton, UK and Saskatchewan, Canada. RESPeRATE itself is produced in Nazareth, Israel.

RESPeRATE Customer Facts

• 90% of RESPeRATE owners are satisfied with the device and are still using it regularly after eight to twelve weeks.
• Two-thirds of owners would definitely recommend RESPeRATE to a friend.
• Already 20% of primary care physicians in the US are aware of RESPeRATE. 6 out of 10 of these physicians recommend the product.
• 90% of RESPeRATE owners are over the age of 50 (equally male and female).
• 2/3 of RESPeRATE owners are on medications, most of whom suffer from side effects and almost all of whom have previously tried diet and exercise to lower their blood pressure.

Corporate Milestones

• InterCure secures nationwide distribution agreement with Lloyds
  Pharmacy Group, the leading community pharmacy chain in the UK.
• Website ranked No. 2 by visits among all US websites in the Hitwise Health and Medical - Pharmaceutical and Medical Products industry.
  
• RESPeRATE attains its 100,000th user.

• InterCure names Scot Dube Vice President of Sales.


• InterCure, Ltd receives Deloitte Technology Fast 50 and Fast 500 Award.


• InterCure and High Tech Health announce RESPeRATE launch into pharmacy market in Australia.


• InterCure and Mashco announce launch into independent pharmacies in the United Kingdom.


• InterCure and Omron Healthcare (UK) Ltd. announce marketing collaboration for hypertension market in United Kingdom.


• On July 26th 2007, InterCure completed its IPO on the Tel Aviv Stock Exchange and raised $16M in common shares and convertible bonds (TASE: INCR).


• California Technology Assessment Forum (CTAF), a program of the Blue Shield of California Foundation, finds RESPeRATE meets its safety and effectiveness criteria.


• 10th clinical study finds RESPeRATE effective in lowering blood pressure for diabetic hypertensives.

• InterCure expands its direct-to-consumer operation in the UK; Print advertising campaign begins in over 100 daily newspapers in the UK and the US.
  
• RESPeRATE attains its 50,000th user.
  
• Website becomes the most popular hypertension destination.
  
• RESPeRATE Duo™ introduced allowing two users to track progress in separate memories (on a single device).
  
• Distribution agreement for RESPeRATE in Japan.
  
• A paper written by two opinion leaders in Hypertension published in Med Gen Med (Medscape General Medicine) reviewed results of RESPeRATE's seven clinical studies. Additional eighth & ninth clinical studies confirmed RESPeRATE's efficacy in Asians and in patients suffering from both diabetes and hypertension.

• InterCure awarded Hypertension Treatment Technology Innovation of the year by Frost & Sullivan.
  
• InterCure focuses on online marketing to promote RESPeRATE in a cost effective manner; Series C investment round secured.

• 10,000 satisfied users; Wall Street Journal & Washington Post rave about RESPeRATE.
  
• Korean FDA and other key markets clear RESPeRATE.

• RESPeRATE begins selling in the US; Limited funding hinders on product launch.
  
• Seventh study demonstrates RESPeRATE's therapeutic powers in resistant hypertensive patients.
  

• FDA clears RESPeRATE for OTC use following successful US-based, multi-center, randomized controlled study (study #6).

• Fourth and fifth clinical studies successfully demonstrate RESPeRATE's efficacy in lowering blood pressure when measured with 24-ambolutory and/or home blood pressure monitors.
  
• Series B funding secured.
  
• Scientific Advisory Board is established.

• FDA clears RESPeRATE as a hypertension treatment device under doctors prescription (Rx), based on successful results of three randomized controlled studies.
  
• InterCure Inc., commences operation in NY after Series A funding is secured.

• InterCure commences operations after seed financing secured.

• InterCure Ltd. is incorporated in Israel.

Next: History